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Abstract  
Dermatomyositis (DM) is a rare connective corresponding to an inflammatory disease of skeletal muscles. Paraneoplastic origin must always be 
sought, primarily gynecological tumor in women, but the investigations are often made difficult by the fact that a primary tumor is often not 
detectable at the time of the cutaneous manifestations. This approach includes in addition to the monitoring report at regular intervals of 6 to 12 
months for two years after diagnosis. We report a case of Dermatomyositis revealing breast cancer. 
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Paraneoplastic syndromes are a collection of disorders affecting an 
organ or tissue caused by cancer but occurring at a site distant from 
the primary or metastases. Dermatomyositis can occur in 
association with malignancy as a paraneoplastic phenomenon [1]. 
Dermatomyositis is a rare connective corresponding to an 
inflammatory disease of skeletal muscles. Paraneoplastic origin must 
always be sought, primarily gynecological tumor in women, but the 
investigations are often made difficult by the fact that a primary 




Patient and observation 
 
38 year old woman with no significant medical history admitted to 
the dermatology department for management of dermatomyositis 
which restraint on clinical (Figure 1), biological, electromyographic 
and pathological criteria. An etiological looking for an initial 
paraneoplastic origin was back negative, outside a ACR3 lesion in 
the upper-inner quadrant of the left breast requiring radiological 
monitoring. The patient was put under high dose of steroids without 
a clear clinical improvement, mammography ultrasound control of 
six months revealed a ACR5 lesion in the same quadrant (Figure 
2). Moreover, clinical breast screening examination remained 
normal. The echo guided biopsy objectified infiltrating ductal 
carcinoma grade II SBR. An additional surgical management was 
decided with achieving a conservative treatment after ultrasound 
localization of the lesion. The patient was put under adjuvant 
chemotherapy and radiotherapy with favorable Evolution with a 1 





Dermatomyositis (DM) is an uncommon idiopathic inflammatory 
myopathy that primarily affects skeletal muscle and skin with well 
characterized cutaneous findings. The estimated incidence of 
dermatomyositis is approximately 1/100,000. DM can affect both 
children and adults, and is more common in women than men (2:1). 
It has been well documented that DM carries an increased risk of 
malignancy and can present as a paraneoplastic syndrome to 
multiple types of underlying malignancies. DM is an autoimmune 
disorder characterized by inflammatory muscular and cutaneous 
disease. Clinically, it manifests with proximal muscle weakness and 
a typical skin rash. DM has been found to be a paraneoplastic 
phenomenon in 15% to 30% of adult patients [2]. In Malaysia, 
Tang and Thevarajah reported in 2010 that 47.4% of 
dermatomyositis patients had underlying malignancy [3].  
  
The pathogenic relationship between dermatomyositis and cancer is 
not fully understood. It would appear that the regenerating cells 
that appear in muscles with myositis express high levels of the 
specific antigens of myositis, and that these are the same as those 
expressed in various cancers associated with inflammatory 
myopathies. The link between cancer and dermatomyositis would 
thus appear to be the expression of antigens common to the cancer 
and to muscle tissue in some patients with dermatomyositis [4]. 
Paraneoplastic dermatomyositis can precede, coincide with, or 
develop after the diagnosis of cancer. Of all the parameters studied, 
it would appear that those most consistently associated with a 
higher risk of cancer in patients with adult dermatomyositis are male 
gender and more advanced age. One clinical trait that has repeat-
edly been related with paraneoplastic dermatomyositis in the 
literature is skin necrosis. In Europe, the cancers associated with 
adult dermatomyositis include, in order of frequency, ovary,lung, 
breast, colon and rectum, stomach, and pancreas .Other associated 
cancers include prostate and non-Hodgkin lymphoma.  
  
The most common cancers associated with adult dermatomyositis in 
women are breast and ovary [4]. The risk of developing a specific 
type of cancer associated with dermatomyositis is unequal in 
different populations. Hill et al. reported on specific cancer types in 
dermatomyositis in Sweden, Denmark and Finland, where ovarian, 
lung and pancreatic cancers were reported as the three main types 
of cancers associated with dermatomyositis. In Scotland, lung 
cancer was the most common cancer related to dermatomyositis, 
while in Tunisia it was breast cancer [5]. Regarding the 
management of paraneoplastic dermato-myositis, our aim must 
always be to control the underlying neoplasm [4]. Topical emollients 
and steroids are important for all patients, and may control the skin 
lesions symptomatically until the tumor itself is treated and the DM 
regresses. If the tumor cannot be treated quickly and radically, then 
the patient will probably require oral corticosteroids. High-dose 
intravenous immunoglobulin has shown to be beneficial for 
recalcitrant DM. Hydroxychloroquine is quite effective in about 80% 
of DM patients when used as a steroid-sparing agent. 
Immunosuppressors, such as methotrexate, azathioprine or 






The diagnosis of dermatomyositis requires etiological looking for a 
paraneoplastic origin. This approach includes in addition to the 
monitoring report at regular intervals of 6 to 12 months for two 
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Figure 1: gottron papules  
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Figure 2: ACR5 lesion 
 
 
